Functional and Therapeutic Significance of Tumor-Associated Macrophages in Colorectal Cancer

Yitong Li1,2†, Zhenmei Chen1,2†, Jiahao Han1,2, Xiaochen Ma1,2, Xin Zheng1,2 and Jinhong Chen1,2*

1 Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China, 2 Cancer Metastasis Institute, Fudan University, Shanghai, China

The role of the tumor microenvironment (TME) in the progression of colorectal cancer (CRC) and its acquisition of resistance to treatment become the research hotspots. As an important component of TME, the tumor-associated macrophages (TAMs) regulate multiple critical oncogenic processes, namely, occurrence, proliferation, metastasis, and drug resistance in CRC. In this review, we have discussed the functional and therapeutic significance of TAMs in CRC. M1 macrophages act as the tumor suppressor while M2 macrophages promote CRC. The polarization of TAMs is mainly regulated by the pathways such as NFKB1 pathways, STAT3 pathways, WNT5A pathways, and PI3K pathways in CRC. Furthermore, the M2 polarization of TAMs is not only controllable but also reversible. Finally, we provide insights into the TAMs-targeted therapeutic strategies.

Keywords: colorectal cancer, tumor-associated macrophages, mechanism, tumor microenvironment, treatment

INTRODUCTION

CRC is the third common cancer in males and second in females, causing 600,000 deaths per year (1). Surgery, chemotherapy, radiotherapy, and targeted therapy are currently established as commonly used options for CRC patients (2–4). With advances in therapeutic strategies, the prognosis of CRC patients has been tremendously improved (5). Patients with stage IIIC colon cancer have a 5-year survival rate of 53%, while 58% for stage IIIC rectal cancer (6). However, drug resistance of CRC is common that prevents treatment from achieving the expected outcome (5, 7). The treatment effect is not very satisfactory due to resistance. Patients with BRAF V600E-mutated metastatic colorectal cancer only have a median overall survival of 4 to 6 months due to multidrug resistance (11). Therefore, effective strategies are urgently needed to improve patient prognosis.

At present, TME plays an essential role in CRC and gradually gains prominence as a new therapeutic target for the reversal of resistance (12, 13). Advances in the understanding of the TME have contributed to the exploration of treatments for advanced CRC (14). To date, pembrolizumab and nivolumab, two anti-programmed death protein 1 (PDCD1) inhibitors, were approved by the FDA for treating mismatch-repair-deficient (dMMR) and microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) (15). Although clinical data have revealed that
immunotherapy can double progression-free survival (PFS), the treatment can only be applied in patients with MSI-H-dMMR CRC, accounting for 15% of all CRC cases (16, 17). The limitation has prompted the search for novel therapeutic targets to improve clinical applications and the effects of immunotherapy.

TME is a complex network comprising cells (T cells, B cells, TAMs, myeloid-derived suppressor cells, cancer-associated fibroblasts, etc.) and non-cellular components (cytokines, proteins, oxygen, etc.) (18–22). As the main component of TME, TAMs can interact with tumor cells by secreting cytokines, participating in CRC processes (23–26). For example, TAMs secret CXCL8 triggering EGFR signaling of tumor cells which is the leading cause of drug resistance in refractory CRC with KRAS or BRAF V600E mutation (27). The expression of immune checkpoints such as PDCD1 in TAMs contributes to immunosuppressed microenvironment in CRC (25, 28–32). With high plasticity and heterogeneity, functions of TAMs in CRC are not limited to immunosuppression, and the M1 phenotype in TAM acts as an immunostimulator (33–35). The phenotypic plasticity in TAMs provides new insights for treatment. A lot of evidence has also revealed that phenotypes and infiltration of TAMs were related to the prognosis of CRC patients (36–39). Consequently, TAMs-targeted therapy is beneficial to improve therapy effectiveness and patient prognosis. The article aims to discuss the multiple roles of TAMs in CRC and summarize emerging treatments based on TAMs.

**TAMs INTERACT WITH COMPONENTS OF TME**

The development of novel anti-CRC treatment has been challenged by the complex tumor environment (40). Many studies also demonstrate that increased pro-tumor cells (such as T-reg cells) and decreased anti-tumor cells (such as CD8 T cells and NK cells) are responsible for tumor escaping immune surveillance (41, 42). Hence, understanding the tumor microenvironment is essential to develop efficient treatment strategies. The TME consist of cancer cells, tumor-associated neutrophils (TANs), myeloid-derived suppressor cells (MDSCs), cancer-associated fibroblasts (CAF), tumor infiltrating lymphocytes (TILs), dendritic cells and all kinds of cytokines, and has been gradually confirmed to improve the malignant potential of tumors (43). TAMs, acting as an important component of TME, can not only directly act on tumor cells but also regulate other constituents of the TME, thus affecting tumor progression (44).

TANs have functional similarities to TAMs. Both cells above exert a dual effect on CRC development with several isorhoms, but the interactions between TAMs and TANs in CRC need to be further investigated (45, 46). MDSCs possess immunosuppressive properties (47). In CRC, TAMs could shape the inflammatory microenvironment by secreting cytokines to promote MDSC production and the recruitment of MDSCs contributes to the generation of TAMs (47, 48). This activation loop between TAMs and MDSCs help tumor expansion and immune evasion. Furthermore, TAMs induce matrix deposition and collagen fibrillogenesis by increasing the expression of collagens XIV and I in CAFs, forming tissue barriers for CRC invasion and metastasis (49). Similar to MDSC, CAFs also act on TAMs. Studies have shown that immunosuppressive factors secreted by CAFs induce polarization of M2-like TAMs (50). In terms of CRC prognosis, both TAMs and TILs have the potential to predict tumor recurrence and survival in CRC patients and the high density of TAMs and TILs indicates a longer survival (51). But the correlation between TAMs and TILs, just like that between TAMs and dendritic cells, still need further exploration (52). One of inflammation hallmarks of TAMs is the cytokine secretion (53). For example, the IL6 secreted by TAMs could promote CRC self-renewal and metastasis (54). TAMs can also expel proteins and enzymes including DOCK family through vesicle transport to mediate the activation of lymphocytes (55). The polarization procedure of TAMs requires the participation of cytokines including IL4, IL10 and so on (56, 57).

As we can see, TAMs interact with multiple constituents in TME to participate in the regulation of CRC. However, the current studies about the interaction between TAMs and immune-related factors are imperfect, which limits our ability to develop specific therapeutic treatments. It is undeniable that TAM plays an important role in CRC and further exploration of its specific role in the various processes of CRC should be conducted in order to find breakthrough points in interventions.

**THE FUNCTIONS OF TAMs IN CRC**

Initially, TAMs exist in the form of undifferentiated macrophages M0, and under some conditions, M0 could be polarized into M1 (generated by classical activation) or M2 phenotype (generated by alternative activation) (Figure 1) (58, 59). Stimulators of classical pathway, namely, bacterial components, interferon-γ (IFNG), lipopolysaccharide (LPS), and Toll-like receptor (TLR), polarize M0 into M1 phenotype, which exerts cancer inhibitory effect by releasing pro-inflammatory cytokines (such as IL1B and IL12) and cytotoxic substances (such as reactive oxygen species and TNF) (60–62). While M2 macrophages display tumor-promoting activity and can be further classified into four different subtypes, M2a (induced by IL4, IL13), M2b (induced by TLR), M2c (induced by glucocorticoid), and M2d (induced by IL6 and adenosines) (63). In vivo, with lower CCL22, CCL17, and IL12 expression, M2 cells secrete a series of molecules such as IL6 and CXCL8 to exert immunosuppressive functions (60, 64). Further insight into the functions of TAMs in CRC is the basis for effective therapeutic targeting.

**CRC Occurrence**

A prospective cohort study showed the amount of TAMs could change the effect of smoking on CRC occurrence (65). However
The mechanisms of correlation between TAMs and CRC occurrence remain unclear. Cancer Stem Cell (CSC) is a kind of cancer cell phenotype having abilities of self-renewal, clonal tumor initiation, and rapid proliferation, taking part in tumorigenesis as the primary cell group (66). Therefore, in this part, we focus on the interaction between TAMs and CSC. In cancer cells, high expression of T-cell immunoglobulin domain and mucin domain 4 (TIMD4) and SIX1 protein indicates upregulated CSC-like properties. These cells would recruit TAMs and promote M2 polarization, leading to tumor progression.
interstitial remodeling (67, 68). In addition to proteins, RNAs regulate the functions of CSC. CSC could downregulate several microRNAs through a circRNA–microRNA–mRNA axis, thus assist the aggregation of downstream molecules, including SKIL, SMAD2, WNT5A, and so on (69).

Meanwhile, in clinical samples, it was found that overexpression of WNT5A could polarize TAMs into the M2 phenotype and regulate IL10 secretion (57). Nevertheless, the reason for the upregulation of WNT5A remains unclear. As in mammalian cells, microRNAs would be packed into exosomes to discharge and function extracellularly (70). There might be a possibility that CSC excretes microRNAs to connect with TAMs. Simultaneously, CSC is regulated by TAMs, and recent in vivo studies suggest the proportion of CD68+ TAMs at the tumor invasive front (TF) is correlated with the level of stem cell marker CD44v6 (71, 72). After infiltrating in the cancer area, M2 subtypes increase the ratio of CD44+CD166+ tumor cells and the expression of acetaldehyde dehydrogenase 1 (ALDH1), which is the marker of CSC (57, 67, 73).

**CRC Proliferation**

Many components of the immune microenvironment are implicated in proliferation, which is a primary hallmark of tumor (74). At present, the role of TAM in CRC proliferation has been widely reported. Through secreting transforming growth factor β1 (TGFβ1), TAMs have abilities to upregulate vascular endothelial growth factor (VEGF) and interleukin-6 (IL6), and the latter binds with IL6 receptor on the tumor cell surface to promote CRC proliferation via activating STAT3 (75, 76). The extent of STAT3 activation is affected by diet, and dieting is considered a potential therapy that promotes anti-tumor immunity (77). Under fasting conditions, M2 polarization was inhibited, resulting in limited proliferation and increased apoptosis of CT26 colon cancer cells (78). A current study provided an important observation that serum starvation caused differentiation markers of T-reg, TGFβ1, and FOXP3 rising (79). This evidence leaves us some questions that if TAMs could play a role in T-reg and regulate the functions of CSC. CSC could downregulate several microRNAs through a circRNA–microRNA–mRNA axis, thus assist the aggregation of downstream molecules, including SKIL, SMAD2, WNT5A, and so on (69).

**CRC Metastasis**

During the malignant transformation, cancer cells undergo function acquisition and alteration due to genetic mutation (81). Among all the functions, the capacity of invasion is an essential criterion for judging malignant diseases (82). Many studies have observed that TAMs accelerate tumor invasion mainly by regulating the epithelial–mesenchymal transition (EMT) process during which tumor cells gradually discard epithelial characteristics and obtain mesenchymal phenotypes, generating circulating tumor cells and tumor stem cells (83, 84). After a positive correlation between TAMs and the EMT marker snail was observed, TAMs were confirmed to release transforming growth factor β (TGFβ) to activate the TGFβ/Smad2,3-4/Snail signaling pathway, and restraining the pathway with TGFβ receptor inhibitor might reverse metastasis (84).

**Prognosis in CRC**

The degree of macrophage infiltration can indirectly reflect the prognosis of patients (90). The risk of recurrence and cancer-associated mortality was doubled in patients with high M2 proportion in lesion compared with low M2 infiltration, and the high invasion of M1 macrophages in tumor matrix predicted a good prognosis and extended survival period (91). To further substantiate this, a subset of 168 patients with stage II/III colorectal cancer received follow-up interviews after operation. The results demonstrated that the patients with a high density of CD163+ TAMs have worse overall survival (OS) and progression-free survival (PFS) (92). For CRC patients, early detection and diagnosis are of great significance for a good outcome, and carcinoembryonic antigen (CEA), the most used biomarker for noninvasively detection, is less effective due to poor sensitivity (93). As same as CEA, TAMs are also distributed in the blood and barely influenced by surgery status (91, 92, 94). Prognostic information can be acquired by analyzing the proportion and polarization state of TAM, such as the ratio of CD206+/CD68+ TAM (95). A study consisting of 931 colorectal cancer patients showed the high M1/M2 ratio was suggestive of lower mortality in colorectal cancer (96). In a word, the infiltration density and polarization state of TAMs influence the prognosis of patients, yet the potential for reflecting prognosis needs further more clinical research (39).

**TAMs AND ABERRANT SIGNALING PATHWAYS**

Colorectal cancer is a highly heterogeneous disease due to the disorder of cell signal regulation mechanism (97). Abnormal activation of pathways is involved in the CRC cell–TAM regulatory loop, which contributes to tumor biology (98, 99).
Consequently, the pathway is like a bridge to connect tumor and TAMs, and TAMs have been proved to be involved in many pathways important to CRC, namely, NFKB1 pathway, STAT3 pathway, WNT5A pathway, and PI3K pathway (Figure 2) (75, 98, 100, 101). While less evidence indicates tumor associated macrophages interact with Hedgehog pathway and Notch pathway, both of which are concerned with regeneration and renewal of the epithelium, this may be a pointcut for better understanding the role of TAMs in CRC (102, 103). This part will summarize the interaction between TAMs and four pathways frequently reactivating in colorectal cancer.

**NFKB1 Signaling Pathway**

Src homology 2 domain-containing tyrosine phosphatase 2 (SHP2) has a tumor inhibitory effect in CRC. When SHP2 is deficient in TAMs, the phosphorylation of RELA protein is declined. It facilitates the polarization of TAMs to M2 phenotype, which can release IL6 and CXCL8 to increase the expression of TNF in CRC cells, leading to the activation of NFKB1 pathway and then promotes tumor angiogenesis and metastasis (26, 104). This procedure emphasizes the importance of epigenetics in TAMs. And enhancing the phosphorylation levels of RELA by knocking out N-myc...
downstream-regulated gene 2 (NDRG2) leads to 1kBα upregulating. As a result, the monocyte polarization is induced toward M1-like macrophages, playing an inhibitory role in tumor (105). Additionally, M2 macrophages can secrete TGFβ2 and activate NFKB1 pathway to regulate FERMT2, forming the TGFβ2/NFKB1/FERMT2 axis to promote CRC cells invasion, and NFKB1 inhibitor Bay 11-7082 can reverse functions mentioned above (106, 107). Though there are no findings of associated clinical trials for CRC, all kinds of inhibitors have brought hopes for the treatment.

### STAT3 Signaling Pathway
STAT3 is a component of the IL6 activated acute phase response factor (APRF) complex, which can be activated by various cytokines or growth factors (108). As we mentioned before, TAM can release cytokines, especially IL6, which could bind specific receptors on CRC cell surface, activating JAK2/STAT3 signaling pathway, downregulating tumor suppressor mir-506-3p, and relieve the inhibition of the latter on FOXO1 that results in enhanced invasion and metastasis of CRC (25). Inhibition of this signaling pathway can reverse CRC metastasis caused by nicotinic acetylcholine receptor α7 (α7nAChR) knockout (107). Like IL6, IL10 secreted by CRC could induce TAM polarization to M2 macrophages through CaKMI/EKR/STAT3 pathway and promote cancer cell itself (57). On the contrary, with the effect of mir-221-3p for silencing JAK3/STAT3 activation, M2 TAMs begin exhibiting characteristics of M1 (109). The STAT3 pathway is not a one-way path, but a loop between CRC and TAMs, and the circle could be disrupted if the pathway was interrupted, which needs a lot more research exploring the association between TAMs and members in this loop.

### WNT5A Signaling Pathway
WNT5A is a secreted glycoprotein belonging to the WNT family, and related signaling pathways mainly regulate cell proliferation, angiogenesis, and so on (110). As for CRC, WNT5A is expressed primarily in tumor matrix, especially in TAMs, but its specific biological function and related mechanism are not fully understood, which needs further exploration (57). WNT5A can form a cascade with CaKMI and ERK1. When the pathway is activated, TAM will be polarized to M2 phenotype and release IL10, aiming to promote the progression of tumor (57, 106). For the tight association of WNT5 with chemokine ligands, researchers subsequently focused on another molecule CCL2, and it was interesting that when WNT5A was used to treat undifferentiated macrophages, CCL2 mRNA was upregulated most significantly among all cytokines (111, 112). After silencing WNT5A expression, the level of ERK activation and expression of CCL2 declines, consequently inhibiting M2 polarization (111). As we all know, non-single but multiple pathways involve in CRC. For instance, the WNT5A pathway could link to the NFKB1 pathway under the action of ROR1, then sensitizing STAT3 (113). Therefore, the WNT5A signaling pathway plays an important role in CRC malignant biological behavior and macrophage infiltration, yet we still know little about how different pathways connect.

### PI3K Signaling Pathway
Phosphatidylinositol-3-kinase (PI3K) signaling pathway is intracellular, which can be activated by lots of cytokines, affecting TAM recruitment and polarization (114). Tumor cells can release succinate acting on macrophages and promote their transformation through the PI3K–hypoxia–inducible factor 1α (HIF1A) axis (22). MiR-934 is one of the activating factors released by exosomes, downregulating the expression of PTEN in TAM, consequently activating the PI3K/AKT1 signaling pathway to induce the M2 polarization (115). In addition to microRNA, CRC can also release type Iy phosphatidylinositol phosphate kinase (PIPKIG) to trigger PI3K/AKT1/MTOR signaling pathway, promoting TAM recruitment in tumor area through reinforcement of CCL2 transcription, thus providing an appropriate environment for CRC development (116). M2 macrophages also release CXCL13 to trigger CXCL13/CXCR5/NFKB1 signaling to induce CRC liver metastasis (115).

### TAM ASSOCIATED TREATMENT
Systematic chemotherapy is the standard treatment for patients with advanced CRC, which can effectively prolong the overall survival time. Whereas the survival rate of patients with stage IV CRC is only 10%, drug resistance was one of the causes of this phenomenon (117). With deepening research, TME immune components are shown to participate in resistance, which is demonstrated by great strides in immunotherapy (118, 119). Primarily programmed by TME, TAMs have a significant impact on the treatment efficiency of CRC (54, 120). It was found that the conditional medium from M1 could improve the oxaliplatin sensitivity in tumor-bearing mice and that from M2 reduces the sensitivity of CRC to 5-fluorouracil (5-FU), suppressing caspase-mediated apoptosis to protect tumor cells from chemotherapy (121, 122), whereas reducing TAM proportion or inducing M1 directional polarization can effectively increase the survival time of patients and improve the prognosis (123, 124). Though M1 and M2 macrophages antagonize each other, interference of TAM gene expression by exogenous application of drugs can reduce the proportion of M2 TAMs in tumor infiltration regions and promote the transformation from M2 to M1 phenotype exerting tumor inhibition (Figure 3) (58, 105, 125). Additionally, the drug tolerance initiated from TAMs is concerned with efflux. Given the difficulties in finding novel therapeutic targets, efflux inhibitors specifically targeted M2 subtype might work miracle.

### TAM as a Target for Immunotherapy
Immunotherapy, namely, immune checkpoint inhibitors, adoptive cell therapy, and tumor vaccines, has been popularized in CRC treatment (126). Programmed cell death protein 1 (PDCD1) is an immune checkpoint receptor. It has been reported that in CRC patients with high microsatellite instability, PDCD1 is highly expressed in M2 macrophages at the invasive region of CRC (127). The high PDCD1 expression of M1 phenotype, resulting in the degeneration of TAM phagocytosis, is positively correlated with disease state of CRC (128). PDCD1 blockers can enhance phagocytic ability of
macrophages and prolong survival time of patients, confirming that PDCD1 therapy can directly aim at TAM. Besides, patients with more M2 macrophages infiltration in lesion areas have the potential to acquire better efficacy. As for adoptive cell therapy, the anti-tumor efficiency of the combination of tumor-directed anti-mesothelin CAR-T cells and M2 inhibitors has been verified, and TAM-associated adoptive cell therapy based on its specific markers, such as CD40, are being investigated (129). In cell models that stably express ovalbumin (OVA) peptide, the OVA vaccine could reduce the density of TAMs in CRC tissue, thus limiting tumor growth, and supplemental application of VEGFC/VEGFR3 neutralizing antibody could further inhibit the chemotaxis of M2 macrophages into CRC area, preventing CRC from escaping immune monitoring (130).

**Directional Regulation of TAM Polarization**

The long non-coding RNAs (lncRNAs) serve as both non-invasive biomarkers and targeted molecules in CRC (131). For instance, lncRNA RPPH1 secreted by CRC cells mediates M2 polarization, promoting tumor metastasis, but is lacking independent means of intervention (132). Intestinal microflora, an important regulator of intestinal microenvironment, has been shown to modulate lncRNA gene expression in various tissues (133). Additionally, microflora can also induce M0 to M2 phenotype polarization by secreting cathepsin K (CTSK), which binds to toll-like receptor 4 (TLR4), activating MTOR pathway (134). CTSK-specific inhibitor Odanacatib is administrated to curb the related pro-tumor effects, improving the prognosis of CRC patients (134). In addition to the regular medications, researchers nowadays exploited nanoparticles with inflammatory molecule releasing ability, Ru @ ICG-BLZ NP, which has high CRC specificity and low toxicity (125). It can release CSF-1R kinase inhibitor BLZ945 and repolarized TAM to M1 macrophages to show an anti-tumor effect which provides a new idea for clinical transformation of nanodrugs (125).
Inhibition of TAM Recruitment or Infiltration

Homologous protein SIX1 is widely expressed in all kinds of cancers, and its overexpression results in upregulation of macrophage-specific colony stimulating factor, thus recruiting pro-tumor TAM in the CRC region (68). Its inhibitor, Nitazoxanide, is expected to silencing SIX1 by suppressing WNT/CTNNB1 pathway (135, 136). Metabolism disturbance could partly explain the mechanism for TAMs inducing drug resistance. Trifluridine/Tipiracil is a new anti-metabolism drug, and its combination with oxaliplatin can effectively exhaust M2 macrophages, thereby causing cytotoxic CD8+ T cell infiltration to compel tumor cell lysis (137). Through years of treatment, clinicians observed a strange phenomenon that patients with colitis have a specific resistance to CRC, but the mechanism is unknown. One of the benign disease characteristics is chronic inflammation that persists for a long time, and many inflammatory factors are involved in this process. Macrophage inhibitory cytokine (MIC) is one of them, which can recruit M0 macrophages and T cells to lesion sites and exert tumor immune regulation (138). Subsequently, more clinical trials are required to explore the anti-CRC effect of MIF biological agents. The combination between it and conventional therapy may provide more options for clinical CRC treatment.

DISCUSSION

A growing understanding of the functions and regulatory mechanisms of TAMs will enable us to explore their future clinical applications in CRC. In this review, we described different subtypes of TAMs and their associated mechanisms in colorectal cancer. Based on the above, TAMs-related treatment for CRC was summarized with potential for further research. Many factors are associated with the poor prognostic of CRC, especially the low early diagnostic rate and poor pharmacological reaction. Therefore, it is of great significance to explore the relevant mechanisms and early diagnostic methods beneficial to clinical prevention and treatment of CRC. TAM is an important component of the TME that mediates CRC proliferation, metastases, drug resistance, and so on. Once stimulated by tumor-associated factors, TAMs migrate to the tumor area at first, occurring polarization to M1 or M2 phenotype, and exerts tumor inhibition or promotion effects, respectively. Nevertheless, whether TAM already exists or transferred from the circulatory system in the CRC tumor area is still doubtful. Additionally, the function of TAM is mostly indirectly proved, and clinical research focusing on TAM is still lacking.

TAMs secrete cytokines (IL6, IL10, etc.) and exosomes (miR-21-5p, miR-155-5p, etc.) through NFkB1 signaling pathway, STAT3 signaling pathway, and other pathways to act on tumor cells and immune cells, regulating the process of CRC. Moreover, TAMs secrete many immunomodulatory proteins in the form of vesicles to consolidating the tumor-promoting roles of stromal cells. Apart from acting on tumor cells, TAMs could regulate other immune cells of TME, thus participating in the regulation of immune microenvironment. That phenomenon may be the cause of treatment failure. Drug resistance is one of the most troublesome problems during the treatment of CRC, and TAM polarization is closely related to the resistance. Especially, M2 phenotype can secrete various factors such as CCL2 to weaken the sensitivity of CRC to oxaliplatin and other drugs, which suggest that TAM is expected to become a tumor therapeutic target. The induction of directional differentiation in vitro is helpful to understand the capacity of different TAM subtypes further. However, the progress of TAM study is slow due to the difficulty of establishing associated models, and there is a long way to address this issue.

Both immune checkpoint inhibitor PDCD1 and tumor vaccine are capable of inhibiting M2 formation or promoting its depletion. PDCD1 takes TAM as a direct target to inhibit tumor progression. The development of nanoscale drug load particles, such as Ru @ ICG-BLZ NP, provides a new method for the clinical transformation of nanodrugs. Since TAMs could release cytokines, neutralizing antibodies against M2 macrophages associated factors also show high anti-tumor value. Limagne et al. (137) found that TAM could also guide direction of T cell infiltration and migration. Therefore, in addition to regulating macrophage polarization states, TAM-targeted therapeutics can improve efficacies of immune checkpoint inhibitors. All of these have shown bright therapeutic prospects and great research potential. However, there are still some limitations. The specific functional mechanism of immunotherapy such as PDCD1 on TAM is still ambiguous. Although TAM is currently considered to be a biomarker, more clinical experiments are required to confirm its efficiency. Furthermore, reactive oxygen species (ROS) can actuate macrophage activation and function (139). Does ROS related mechanism attend TAM tumor regulation process? Whether metabolomics and biological rhythm also affect TAM function, these questions are worthy of further studies. The main biomarkers of TAM, such as CD68, transmembrane receptors, and secretory proteins, are expected to be therapeutic targets (120).

Based on this, CRC-specific immunotherapy has been developed, which shows great application prospects and clinical significance. We follow standardized nomenclature for gene products recommended by experts (140).

AUTHOR CONTRIBUTIONS

YL drafted the manuscript. ZC designed the figures and revised the manuscript. JC has done critical revision, and approved this version of the article. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

FUNDING

This work was supported by the National Natural Science and Technology Major Project of the thirteenth Five Year Plan (grant 2017ZX10203207) and the National Natural Science Foundation of China (grant 8200033791, 8207034966).

ACKNOWLEDGMENTS

The authors thank the Huashan Hospital for supporting information and also thank the Cancer Metastasis Institute for providing the study site.
REFERENCES

1. Kolligs FT. Diagnostics and Epidemiology of Colorectal Cancer. Visc Med (2016) 32(3):158–64. doi: 10.1159/000446488
2. Guo L, Wang C, Qiu X, Pu X, Chang P. Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy. Front Immunol (2020) 11:1052. doi: 10.3389/fimmu.2020.01052
3. Liu K, Lei S, Xiang Y, Jin Q, Long D, Liu C, et al. A Novel Mechanism of the C-Myc/NEAT1 Axis Mediating Colorectal Cancer Cell Response to Photodynamic Therapy Treatment. Front Oncol (2021) 11:652831. doi: 10.3389/fonc.2021.652831
4. Wang H. MicroRNAs and Apoptosis in Colorectal Cancer. Int J Mol Sci (2020) 21(13):3533. doi: 10.3390/ijms21133533
5. Diehl TM, Abbott DE. Molecular Determinants and Other Factors to Guide Selection of Patients for Hepatic Resection of Metastatic Colorectal Cancer. Curr Treat Options Oncol (2021) 22(9):82. doi: 10.1007/s11864-021-00878-5
6. Rawla P, Sunkara T, Barsouk A. Epidemiology of Colorectal Cancer: Incidence, Mortality, Survival, and Risk Factors. Prz Gastroenterol (2019) 14(2):89–103. doi: 10.5147/pp.2018.01072
7. Zhao F, Yang Z, Tian X, Ly Y, Guo Z, et al. Design, Synthesis and Biological Evaluation of Sphingosine-1-Phosphate Receptor 2 Antagonists as Potent S-FU-Resistance Reversal Agents for the Treatment of Colorectal Cancer. Eur J Med Chem (2021) 225:113775. doi: 10.1016/j.ejmech.2021.113775
8. Wang H. MicroRNAs and Apoptosis in Colorectal Cancer. Int J Mol Sci (2020) 21(15). doi: 10.3390/ijms21153533
9. Chen N, Kong Y, Wu Y, Gao Q, Fu J, Sun X, et al. CACI Knockdown Reverses Drug Resistance Through the Downregulation of P-Gp and MRP-1 Expression in Colorectal Cancer. PLoS One (2019) 14(9):e0222035. doi: 10.1371/journal.pone.0222035
10. Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. Cancer Res (2020) 80(10):3076–87. doi: 10.1158/0008-5472.Can-20-1264
11. Reidy E, Leonard NA, Treacy O, Ryan AE. A 3D View of Colorectal Cancer. Front Immunol (2021) 12:690201. doi: 10.3389/fimmu.2021.690201
12. Wang H. MicroRNAs and Apoptosis in Colorectal Cancer. Int J Mol Sci (2020) 21(13):3533. doi: 10.3390/ijms21133533
13. Luo D, Zhang Y, Yang S, Tian X, Lv Y, Guo Z, et al. Design, Synthesis and Biological Evaluation of Sphingosine-1-Phosphate Receptor 2 Antagonists as Potent S-FU-Resistance Reversal Agents for the Treatment of Colorectal Cancer. Eur J Med Chem (2021) 225:113775. doi: 10.1016/j.ejmech.2021.113775
14. Renkova M, Ma Y, Gaifler N, Chen Y. Metabolic Reprogramming of Colorectal Cancer Cells and the Microenvironment: Implication for Therapy. Int J Mol Sci (2021) 22(12):6262. doi: 10.3390/ijms22126262
15. Godoy A, Christodoulou A, Leonard NA, Abdullaev BO, Xu Y, Kim MY, et al. The Clinical Role of the TME in Solid Cancer. Br J Cancer (2019) 120(1):45–53. doi: 10.1038/s41416-018-0327-x
16. Ganashe K, Stadler ZK, Cerneck A, Mendelhoan RB, Shia J, Segal NH, et al. Immunotherapy in Colorectal Cancer: Rationale, Challenges and Potential. Nat Rev Gastroenterol Hepatol (2019) 16(6):361–75. doi: 10.1038/s41575-019-01126-x
17. Biller LH, Shrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA (2021) 325(7):669–85. doi: 10.1001/jama.2021.0106
18. André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med (2020) 383(23):2207–18. doi: 10.1056/NEJMoa2017699
19. Picoli CC, Gonçalves BOP, Santos GSP, Rocha BGS, Costa AC, Resende RR, et al. Pericyte Cross-Talks Within the Tumor Microenvironment. Biomaterials (2020) 388:113293. doi: 10.1016/j.biomaterials.2019.113293
20. Yamaguchi R, Perkins G. Animal Models for Studying Tumor Microenvironment (TME) and Resistance to Lymphocytic Infiltration. Cancer Biol Ther (2018) 19(9):745–54. doi: 10.1080/15384047.2018.1470722
21. Liu Y, Zhou X, Wang X. Targeting the Tumor Microenvironment in B-Cell Lymphoma: Challenges and Opportunities. J Hematol Oncol (2021) 14(1):125. doi: 10.1186/s13045-021-01134-x
39. Li J, Li L, Li Y, Long Y, Zhao Q, Ouyang Y, et al. Tumor-Associated Macrophage Infiltration and Prognosis in Colorectal Cancer: Systematic Review and Meta-Analysis. Int J Colorectal Dis (2020) 35(7):1203–10. doi: 10.1007/s00384-020-03593-z
40. Ruan H, Leibowitz BJ, Zhang L, Yu J. Immunogenic Cell Death in Colon Cancer Prevention and Therapy. Mol Carcinog (2020) 59(7):783–93. doi: 10.1002/mc.23183
41. Pacione M, Giordano G, Remo A, Febbraro A, Sabatino L, Manfrin E, et al. Immune Escape Mechanisms in Colorectal Cancer Pathogenesis and Liver Metastasis. J Immunol Res (2014) 2014:688679. doi: 10.1155/2014/688679
42. Westrich JA, Vermeer DW, Colbert PL, Spanos WC, Pyeon D. The Multifarious Roles of the Chemokine CXCL14 in Cancer Progression and Immune Responses. Mol Carcinog (2020) 59(7):794–806. doi: 10.1002/ mc.23188
43. Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. Targeting
44. Ngambenjawong C, Gustafson HH, Pun SH. Progress in Tumor-Associated
47. Maisonneuve C, Tsang DKL, Foerster EG, Robert LM, Mukherjee T, Prescott
42. Westrich JA, Vermeer DW, Colbert PL, Spanos WC, Pyeon D. The
48. Lin X, Wang S, Sun M, Zhang C, Wei C, Yang C, et al. miR-195-5p/
49. Li J, Li L, Li Y, Zhao Q, Ouyang Y, et al. Tumor-Associated Macrophage Infiltration and Prognosis in Colorectal Cancer: Systematic Review and Meta-Analysis. Int J Colorectal Dis (2020) 35(7):1203–10. doi: 10.1007/s00384-020-03593-z
40. Ruan H, Leibowitz BJ, Zhang L, Yu J. Immunogenic Cell Death in Colon Cancer Prevention and Therapy. Mol Carcinog (2020) 59(7):783–93. doi: 10.1002/mc.23183
41. Pacione M, Giordano G, Remo A, Febbraro A, Sabatino L, Manfrin E, et al. Immune Escape Mechanisms in Colorectal Cancer Pathogenesis and Liver Metastasis. J Immunol Res (2014) 2014:688679. doi: 10.1155/2014/688679
42. Westrich JA, Vermeer DW, Colbert PL, Spanos WC, Pyeon D. The Multifarious Roles of the Chemokine CXCL14 in Cancer Progression and Immune Responses. Mol Carcinog (2020) 59(7):794–806. doi: 10.1002/ mc.23188
43. Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. Targeting
75. Zhang D, Qiu X, Li J, Zheng S, Li L, Zhao H. TGF-β Secreted by Tumor-Associated Macrophages Promotes Proliferation and Invasion of Colorectal Cancer via miR-34a-VEGF Axis. *Cell Cycle* (2018) 17(24):2766–78. doi: 10.1080/15384101.2018.1556064

76. Liu C, Yao Z, Wang J, Zhang W, Yang Y, Zhang Y, et al. Macrophage-Derived CCL5 Facilitates Escape of Colorectal Cancer Cells via the p65/STAT3-CSN5-PD-L1 Pathway. *Cell Death Differ* (2020) 27(6):1765–81. doi: 10.1038/s41418-019-0460-0

77. Sun P, Wang H, He Z, Chen X, Wu Q, Chen W, et al. Fasting Inhibits Colorectal Cancer Growth by Reducing M2 Polarization of Tumor-Associated Macrophages. *Onco Targets and Therapy* (2017) 8(43):7469–60. doi: 10.18632/onctarget.20301

78. Rahman M, Mohammad-Afrouzi M, Nouri HR, Fatollahi S, Akhavan-Niahi H, Mostafazadeh A. Human PBMCs Flight or Flight Response to Starvation Stress: Increased T-Reg, FOXP3, and TGF-β1 With Decreased miR-21 and Constant miR-181c Levels. *BioMed Pharmacother* (2018) 108:1404–11. doi: 10.1016/j.biopha.2018.09.163

79. Ye YC, Zhao JL, Gao CC, Yang Y, Liang SQ, et al. NOTCH Signaling via WNT Outcomes in the Proliferation of Alternative, CCR2-Independent Tumor-Associated Macrophages in Hepatocellular Carcinoma. *Cancer Res* (2019) 79(16):4160–72. doi: 10.1158/0008-5472.CAN-18-1691

80. Li C, Xu J, Wang X, Zhang C, Yu Z, Liu J, et al. Whole Exome and Transcriptome Sequencing Reveal Clonal Evolution and Exhibit Immune-Related Features in Metastatic Colorectal Tumors. *Cell Death Discov* (2021) 7(1):222. doi: 10.1038/s41420-021-00607-9

81. Huang D, Sun W, Zhou Y, Li P, Chen F, Chen H, et al. Mutations of Key Driver Genes in Colorectal Cancer Progression and Metastasis. *Cancer Metastasis Rev* (2018) 37(1):173–87. doi: 10.1007/s10555-017-9726-5

82. Saitoh M. Involvement of Partial EMT in Cancer Progression. *J Biochem* (2018) 164(4):257–64. doi: 10.1093/jb/mvy047

83. Cai J, Xia L, Li J, Ni S, Song H, Wu X. Tumor-Associated Macrophages Derived TGF-β-Induced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells Through Smad2,3-4/Snail Signaling Pathway. *Cancer Res Treat* (2020) 108:1404. doi: 10.18632/oncotarget.20301

84. Hsu JL, Leung PS, Chan HH, Ho CS, Liu CF, et al. Exosomal microRNA-106b-5p Activates EMT-Cancer Cell and M2-Subtype Macrophage polarization and Kidney Fibrosis by Inducing the Transcriptional Regulators Yap/Taz. *J Biol Chem* (2018) 293(50):19290–302. doi: 10.1074/jbc.RA118.005457

85. Yang C, Dou R, Wei C, Liu K, Shi D, Zhang C, et al. Tumor-Driven Exosomal microRNA-106b-5p Activates EMT-Cancer Cell and M2-Subtype Macrophage Polarization. *J Cell Mol Med* (2021) 25(6):1765–81. doi: 10.1111/jcmm.15728

86. Yan Z, Cheng M, Hu G, Wang Y, Zeng S, Huang A, et al. Positive Feedback of SuFu Negating Protein 1 on Hedgehog Signaling Promotes Colorectal Tumor Growth. *Cell Death Dis* (2021) 12(2):199. doi: 10.1038/s41419-021-00534-2

87. Heuberger J, Grinat J, Kosef L, Liu K, Kusch S, Vidal RO, et al. High YAP and MII Promote a Persistent Regenerative Cell State Induced by Notch Signaling and Loss of P53. *Proc Natl Acad Sci USA* (2021) 118(22):e2019699118. doi: 10.1073/pnas.2019699118

88. Zhang T, Liu L, Lai W, Zeng Y, Xu H, Lan Q, et al. Interaction With Tumor–Associated Macrophages Promotes PRL–3–Induced Invasion of Colorectal Cancer Cells via MAPK Pathway–Induced EMT and NF–κB Signaling–Induced Angiogenesis. *Oncol Rep* (2019) 41(5):2790–802. doi: 10.3892/or.2019.7049

89. Li M, Lai X, Zhao Y, Zhang Y, Li M, Li D, et al. Loss of NDRG2 in Liver Microenvironment Inhibits Cancer Liver Metastasis by Regulating Tumor Associate Macrophages Polarization. *Cell Death Dis* (2018) 9(2):248. doi: 10.1038/s41419-018-0284-8

90. Wang Z, Yang Y, Cui Y, Wang C, Lai Z, Li Y, et al. Tumor-Associated Macrophages Regulate Gastric Cancer Cell Invasion and Metastasis Through Tgfβ2/NF–κB/Kindlin-2 Axis. *Chin J Cancer Res* (2020) 32(1):72–88. doi: 10.21147/j.issn.1000-9604.2020.01.09

91. Fei R, Zhang Y, Wang S, Xiang T, Chen W. α7 Nicotinic Acetylcholine Receptor in Tumor-Associated Macrophages Inhibits Colorectal Cancer Metastasis Through the JAK2/STAT3 Signaling Pathway. *Oncol Rep* (2017) 38(3):2617–28. Q. doi: 10.3892/or.2017.6517

92. Hiller EM, Zhang H, Li HS, Watowich SA. STAT3 Signaling in Immunity. *Cytochrome Cytokin Growth Factor Rev* (2016) 31:1–15. doi: 10.1016/j.cytofgfr.2016.05.001
112. Lee GT, Kwon SJ, Kim J, Kwon YS, Lee N, Hong JH, et al. WNT5A Induces Significance of Programmed Cell Death-Ligand 1 Expression and the Immune Microenvironment at the Invasive Front of Colorectal Cancers With High Microsatsallite Instability. Int J Cancer (2018) 142(4):822–32. doi: 10.1002/ijc.31107
128. Gordon SR, Maute RL, Dulkien BW, Hutter G, George BM, McCracken MN, et al. PD-1 Expression by Tumour-Associated Macrophages Inhibits Phagocytosis and Tumour Immunity. Nature (2017) 545(7655):495–9. doi: 10.1038/nature22396
129. Rodriguez-Garcia A, Lynn RC, Poussin M, Eiva MA, Shaw LC, O'Connor RS, et al. CAR-T Cell-Mediated Depletion of Immunosuppressive Tumor-Associated Macrophages Promotes Endogenous Antitumor Immunity and Augments Adoptive Immunotherapy. Nat Commun (2021) 12(1):877. doi: 10.1038/s41467-021-20893-2
130. Tacconi C, Ungaro F, Correale C, Arena V, Massimino L, Detmar M, et al. Activation of the VEGF/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer. Cancer Res (2019) 79(16):4196–210. doi: 10.1181/00085472.Can-18-3657
131. Liu Y, Wen Y, Chen X, Zhu X, Yu Q, Gong Y, et al. Inhibition of Cathepsin K Secretion Mediates TLR4-Dependent M2 Macrophage Polarization. Cell Death Dis (2019) 10:3087. doi: 10.1038/s41419-019-0152-9
132. Song W, Ma J, Lei B, Yuan X, Cheng B, Yang H, et al. Sine Oculis Homeobox 7 Promotes Proliferation and Migration of Human Colorectal Cancer Cells Through Activation of Wnt/B-Catenin Signaling. Cancer Sci (2019) 110 (2):608–16. doi: 10.1111/cjs.13905
133. Dempsey J, Zhang A, Cui YJ. Coordinate Regulation of Long Non-Coding RNAs and Protein-Coding Genes in Germ-Free Mice. BMC Genomics (2018) 19(1):834. doi: 10.1186/s12864-018-5235-3
134. Li R, Zhou R, Wang H, Li Y, Chen B, Chen W, et al. Gut Microbiota-Stimulated Confluent and Invasive Function by 5-Fluorouracil Adjuvant Therapy. Int J Cancer (2018) 142(1):94. doi: 10.1002/ijc.32747
135. Tacconi C, Ungaro F, Correale C, Arena V, Massimino L, Detmar M, et al. Activation of the VEGF/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer. Cancer Res (2019) 79(16):4196–210. doi: 10.1181/00085472.Can-18-3657
136. Qu Y, Olsen JR, Yuan X, Cheng PF, Levesque MP, Brokstad KA, et al. Small Molecule Promotes B-Catenin CITRULLINATION and Inhibits Wnt Signaling in Cancer. Nat Chem Biol (2018) 14(1):94–101. doi: 10.1038/ nchembio.2510
137. Limagne E, Thibaudin M, Nuttin L, Spill A, Derangère V, Fumet JD, et al. Trifluoridin/Epirubicin Plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages. Cancer Immunol Res (2019) 7(12):1958–69. doi: 10.1158/ 2326-6066.CIR-19-0228
138. Pacheco-Fernández T, Jáurez-Avelar I, Illescas O, Terrazas LL, Hernández-Pando R, Pérez-Plasencia C, et al. Macrophage Migration Inhibitory Factor Promotes the Interaction Between the Tumor, Macrophages, and T Cells to Regulate the Progression of Chemically Induced Collitis-Associated Colorectal Cancer. Mediators Inflamm (2019) 2019:2056085. doi: 10.1155/ 2019/2056085
139. Rendra E, Riabov V, Mossel DM, Sevastyanova T, Harmsen MC, Kehyshkowska J. Reactive Oxygen Species (ROS) in Macrophage Activation and Function in Diabetes. Immunology (2019) 224(2):242–53. doi: 10.1111/jmi.2018.11.010
140. Fujiyoshi K, Bruford EA, Mroz P, Sims CL, O’Leary TJ, Lo AWI, et al. Opinion: Standardizing Gene Product Nomenclature–A Call to Action. Proc Natl Acad Sci USA (2021) 118(3):e2025207118. doi: 10.1073/pnas. 2025207118

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in
Significance of TAMs in CRC

this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Li, Chen, Han, Ma, Zheng and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).

The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.